Your browser doesn't support javascript.
loading
Emerging immunologic approaches as cancer anti-angiogenic therapies.
Azimi, Mohammadreza; Manavi, Mahdokht Sadat; Afshinpour, Maral; Khorram, Roya; Vafadar, Reza; Rezaei-Tazangi, Fatemeh; Arabzadeh, Danyal; Arabzadeh, Sattar; Ebrahimi, Nasim; Aref, Amir Reza.
Afiliación
  • Azimi M; Department of Biochemistry, Medical Faculty, Saveh Branch, Islamic Azad University, Saveh, Iran.
  • Manavi MS; Otolaryngology Department, Tehran University of Medical Science, Tehran, Iran.
  • Afshinpour M; Department of Chemistry and Biochemistry, South Dakota State University (SDSU), Brookings, SD, USA.
  • Khorram R; Bone and Joint Diseases Research Center, Department of Orthopedic Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Vafadar R; Department of Orthopeadic Surgery, Kerman University of Medical Sciences, Kerman, Iran.
  • Rezaei-Tazangi F; Department of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
  • Arabzadeh D; Xi'an Jaiotong University Medical Campus, Xi'an Jaiotong University, Xi'an, Shaanxi Province, China.
  • Arabzadeh S; Xi'an Jaiotong University Medical Campus, Xi'an Jaiotong University, Xi'an, Shaanxi Province, China.
  • Ebrahimi N; Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran. Nasimeb69@gmail.com.
  • Aref AR; Mass General Cancer Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. aaref@mgh.harvard.edu.
Clin Transl Oncol ; 2024 Sep 18.
Article en En | MEDLINE | ID: mdl-39294514
ABSTRACT
Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system's specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Oncol Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Oncol Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Italia